PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Phase II Trial of PEG-Intron in Patients With Advanced Renal Cell Carcinoma

RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Determine the efficacy of PEG-interferon alfa-2b in patients with metastatic renal cell carcinoma.
  • Determine the time to disease progression in patients treated with this drug.
  • Determine the safety of this drug in these patients.
  • Determine the quality of life of patients treated with this drug.
  • Determine the effect of this drug on biological surrogates of antitumor activity (basic fibroblast growth factor, vascular endothelial growth factor, and interleukin-6 serum levels) in these patients.

OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, at 2 weeks and at 2, 4, 8, and 12 months after initiation of study therapy, and then at completion of study therapy.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 15 months.

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10021
        • Memorial Sloan-Kettering Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed renal cell carcinoma

    • Metastatic disease
    • No prior therapy for advanced disease
  • Tumor sample available for molecular analysis with prior registration on MSKCC IRB # 89-076
  • Bidimensionally measurable disease
  • No brain metastases unless completely resected and without evidence of recurrence for at least six months

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified

Hematopoietic

  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3

Hepatic

  • Bilirubin no greater than 1.5 mg/dL
  • SGOT no greater than 2.5 times upper limit of normal (unless due to hepatic metastases)
  • Hepatitis B surface antigen negative
  • Hepatitis C negative

Renal

  • Creatinine no greater than 2 mg/dL

Cardiovascular

  • No severe cardiac disease
  • No New York Heart Association class III or IV cardiac disease
  • No myocardial infarction within the past 12 months
  • No ventricular tachyarrhythmias requiring ongoing treatment
  • No unstable angina

Pulmonary

  • No severe asthma requiring chronic systemic steroids

Other

  • HIV negative
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No malignancy within the past 2 years except basal cell or squamous cell skin cancer, superficial bladder cancer, or localized prostate cancer

    • Patients who have undergone potentially curative therapy and have been deemed to be at low risk for recurrence are eligible
  • No medically significant psychiatric disease (e.g., endogenous depression, psychosis, or bipolar disease) requiring hospitalization
  • No prior or active autoimmune disease
  • Medically controlled diabetes or thyroid dysfunction allowed
  • No clinically significant acute viral or bacterial infection that requires specific therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No prior interleukin-2
  • No prior interferon alfa
  • No concurrent cytokines or biological response modifiers except epoetin alfa in the case of hematologic compromise
  • No concurrent tumor vaccines
  • No concurrent monoclonal antibodies
  • No concurrent bone marrow/stem cell transplantation

Chemotherapy

  • No concurrent cytotoxic agents

Endocrine therapy

  • No concurrent high-dose systemic steroids
  • Concurrent low-dose corticosteroids (e.g., asthma inhalers, topical creams, or intra-articular injections) allowed
  • No concurrent hormonal therapy (including megestrol)
  • Concurrent hormone replacement therapy or oral contraceptives allowed

Radiotherapy

  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • See Disease Characteristics
  • At least 4 weeks since prior major surgery
  • Concurrent nephrectomy allowed

Other

  • At least 14 days since prior anti-infectious therapy
  • No other concurrent investigational drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Masking: None (Open Label)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2002

Primary Completion (Actual)

September 1, 2005

Study Completion (Actual)

September 1, 2005

Study Registration Dates

First Submitted

September 6, 2002

First Submitted That Met QC Criteria

January 26, 2003

First Posted (Estimate)

January 27, 2003

Study Record Updates

Last Update Posted (Estimate)

June 5, 2013

Last Update Submitted That Met QC Criteria

June 4, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Cancer

Clinical Trials on PEG-interferon alfa-2b

3
Subscribe